Skip to main content
Top
Published in: Tumor Biology 7/2014

01-07-2014 | Research Article

RETRACTED ARTICLE: Correlations of IFN-γ genetic polymorphisms with susceptibility to breast cancer: a meta-analysis

Authors: Chun-Jiang Li, Yue Dai, Yan-Jun Fu, Jia-Ming Tian, Jin-Lun Li, Hong-Jun Lu, Feng Duan, Qing-Wang Li

Published in: Tumor Biology | Issue 7/2014

Login to get access

Abstract

The meta-analysis was conducted to evaluate the correlations between common genetic polymorphisms in the IFN-γ gene and susceptibility to breast cancer. The following electronic databases were searched without language restrictions: MEDLINE (1966 ~ 2013), the Cochrane Library Database (issue 12, 2013), EMBASE (1980 ~ 2013), CINAHL (1982 ~ 2013), Web of Science (1945 ~ 2013), and the Chinese Biomedical Database (CBM) (1982 ~ 2013). Meta-analysis was performed with the use of the STATA statistical software. Odds ratios (OR) with their 95 % confidence intervals (95 % CIs) were calculated. Nine clinical case-control studies met all the inclusion criteria and were included in this meta-analysis. A total of 1,182 breast cancer patients and 1,525 healthy controls were involved in this meta-analysis. Three functional polymorphisms were assessed, including rs2069705 C>T, rs2430561 T>A, and CA repeats 2/X. Our meta-analysis results indicated that IFN-γ genetic polymorphisms might be significantly associated with an increased risk of breast cancer (allele model: OR = 1.37, 95 % CI = 1.03 ~ 1.83, P = 0.031; dominant model: OR = 1.55, 95 % CI = 1.01 ~ 2.37, P = 0.046; homozygous model: OR = 2.23, 95 % CI = 1.30 ~ 3.82, P = 0.004; respectively), especially the rs2430561 T>A polymorphism. Subgroup analysis based on ethnicity suggested that genetic polymorphisms in the IFN-γ gene were closely correlated with increased breast cancer risk among Asians (allele model: OR = 1.21, 95 % CI = 1.02 ~ 1.58, P = 0.017; dominant model: OR = 3.44, 95 % CI = 2.07 ~ 5.71, P < 0.001; recessive model: OR = 1.58, 95 % CI = 1.06 ~ 2.37, P = 0.025; homozygous model: OR = 1.83, 95 % CI = 1.19 ~ 2.80, P = 0.006; respectively), but not among Caucasians (all P > 0.05). Our meta-analysis supported the hypothesis that IFN-γ genetic polymorphisms may contribute to an increased risk of breast cancer, especially the rs2430561 T>A polymorphism among Asians.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
2.
go back to reference Guo LJ, Zhang QY. Decreased serum miR-181a is a potential new tool for breast cancer screening. Int J Mol Med. 2012;30(3):680–6.PubMed Guo LJ, Zhang QY. Decreased serum miR-181a is a potential new tool for breast cancer screening. Int J Mol Med. 2012;30(3):680–6.PubMed
3.
go back to reference Brinton LA, Carreon JD, Gierach GL, McGlynn KA, Gridley G. Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat. 2010;119(1):185–92.PubMedCentralCrossRefPubMed Brinton LA, Carreon JD, Gierach GL, McGlynn KA, Gridley G. Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat. 2010;119(1):185–92.PubMedCentralCrossRefPubMed
4.
go back to reference Nickels S, Truong T, Hein R, Stevens K, Buck K, Behrens S, et al. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet. 2013;9(3):e1003284.PubMedCentralCrossRefPubMed Nickels S, Truong T, Hein R, Stevens K, Buck K, Behrens S, et al. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet. 2013;9(3):e1003284.PubMedCentralCrossRefPubMed
5.
go back to reference La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist. 2011;16(6):726–9.PubMedCentralCrossRefPubMed La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist. 2011;16(6):726–9.PubMedCentralCrossRefPubMed
6.
7.
go back to reference Park SK, Kim Y, Kang D, Jung EJ, Yoo KY. Risk factors and control strategies for the rapidly rising rate of breast cancer in Korea. J Breast Cancer. 2011;14(2):79–87.PubMedCentralCrossRefPubMed Park SK, Kim Y, Kang D, Jung EJ, Yoo KY. Risk factors and control strategies for the rapidly rising rate of breast cancer in Korea. J Breast Cancer. 2011;14(2):79–87.PubMedCentralCrossRefPubMed
8.
go back to reference Fontein DB, de Glas NA, Duijm M, Bastiaannet E, Portielje JE, Van de Velde CJ, et al. Age and the effect of physical activity on breast cancer survival: a systematic review. Cancer Treat Rev. 2013;39(8):958–65.CrossRefPubMed Fontein DB, de Glas NA, Duijm M, Bastiaannet E, Portielje JE, Van de Velde CJ, et al. Age and the effect of physical activity on breast cancer survival: a systematic review. Cancer Treat Rev. 2013;39(8):958–65.CrossRefPubMed
9.
go back to reference Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkjaer L, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2013;31(4):433–9.PubMedCentralCrossRefPubMed Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkjaer L, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2013;31(4):433–9.PubMedCentralCrossRefPubMed
10.
go back to reference Bouchardy C, Rapiti E, Fioretta G, Schubert H, Chappuis P, Vlastos G, et al. Impact of family history of breast cancer on tumour characteristics, treatment, risk of second cancer and survival among men with breast cancer. Swiss Med Wkly. 2013;143:w13879.PubMed Bouchardy C, Rapiti E, Fioretta G, Schubert H, Chappuis P, Vlastos G, et al. Impact of family history of breast cancer on tumour characteristics, treatment, risk of second cancer and survival among men with breast cancer. Swiss Med Wkly. 2013;143:w13879.PubMed
11.
go back to reference Su Y, Tang LY, Chen LJ, He JR, Su FX, Lin Y, et al. Joint effects of febrile acute infection and an interferon-gamma polymorphism on breast cancer risk. PLoS One. 2012;7(5):e37275.PubMedCentralCrossRefPubMed Su Y, Tang LY, Chen LJ, He JR, Su FX, Lin Y, et al. Joint effects of febrile acute infection and an interferon-gamma polymorphism on breast cancer risk. PLoS One. 2012;7(5):e37275.PubMedCentralCrossRefPubMed
12.
go back to reference Karakus N, Kara N, Ulusoy AN, Ozaslan C, Bek Y. Tumor necrosis factor alpha and beta and interferon gamma gene polymorphisms in Turkish breast cancer patients. DNA Cell Biol. 2011;30(6):371–7.CrossRefPubMed Karakus N, Kara N, Ulusoy AN, Ozaslan C, Bek Y. Tumor necrosis factor alpha and beta and interferon gamma gene polymorphisms in Turkish breast cancer patients. DNA Cell Biol. 2011;30(6):371–7.CrossRefPubMed
13.
go back to reference Kim K, Cho SK, Sestak A, Namjou B, Kang C, Bae SC. Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus. Ann Rheum Dis. 2010;69(6):1247–50.CrossRefPubMed Kim K, Cho SK, Sestak A, Namjou B, Kang C, Bae SC. Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus. Ann Rheum Dis. 2010;69(6):1247–50.CrossRefPubMed
15.
go back to reference He JR, Chen LJ, Su Y, Cen YL, Tang LY, Yu DD, et al. Joint effects of Epstein-Barr virus and polymorphisms in interleukin-10 and interferon-gamma on breast cancer risk. J Infect Dis. 2012;205(1):64–71.CrossRefPubMed He JR, Chen LJ, Su Y, Cen YL, Tang LY, Yu DD, et al. Joint effects of Epstein-Barr virus and polymorphisms in interleukin-10 and interferon-gamma on breast cancer risk. J Infect Dis. 2012;205(1):64–71.CrossRefPubMed
16.
go back to reference Chou SF. Development of a manual self-assembled colloidal gold nanoparticle-immunochromatographic strip for rapid determination of human interferon-gamma. Analyst. 2013;138(9):2620–3.CrossRefPubMed Chou SF. Development of a manual self-assembled colloidal gold nanoparticle-immunochromatographic strip for rapid determination of human interferon-gamma. Analyst. 2013;138(9):2620–3.CrossRefPubMed
17.
go back to reference Pluddemann A, Mukhopadhyay S, Gordon S. Innate immunity to intracellular pathogens: macrophage receptors and responses to microbial entry. Immunol Rev. 2011;240(1):11–24.CrossRefPubMed Pluddemann A, Mukhopadhyay S, Gordon S. Innate immunity to intracellular pathogens: macrophage receptors and responses to microbial entry. Immunol Rev. 2011;240(1):11–24.CrossRefPubMed
18.
go back to reference Gonullu G, Basturk B, Evrensel T, Oral B, Gozkaman A, Manavoglu O. Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J. 2007;28(11):1728–33.PubMed Gonullu G, Basturk B, Evrensel T, Oral B, Gozkaman A, Manavoglu O. Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J. 2007;28(11):1728–33.PubMed
19.
go back to reference Naylor SL, Gray PW, Lalley PA. Mouse immune interferon (IFN-gamma) gene is on chromosome 10. Somat Cell Mol Genet. 1984;10(5):531–4.CrossRefPubMed Naylor SL, Gray PW, Lalley PA. Mouse immune interferon (IFN-gamma) gene is on chromosome 10. Somat Cell Mol Genet. 1984;10(5):531–4.CrossRefPubMed
20.
go back to reference Erdei E, Kang H, Meisner A, White K, Pickett G, Baca C, et al. Polymorphisms in cytokine genes and serum cytokine levels among New Mexican women with and without breast cancer. Cytokine. 2010;51(1):18–24.PubMedCentralCrossRefPubMed Erdei E, Kang H, Meisner A, White K, Pickett G, Baca C, et al. Polymorphisms in cytokine genes and serum cytokine levels among New Mexican women with and without breast cancer. Cytokine. 2010;51(1):18–24.PubMedCentralCrossRefPubMed
21.
go back to reference Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
22.
go back to reference Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.CrossRefPubMed Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.CrossRefPubMed
23.
go back to reference Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.CrossRefPubMed Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.CrossRefPubMed
24.
go back to reference Wu GH, Zhang JY, Lu PX. Association of single nucleotide polymorphism of interferon-ganuna gene+874 site and breast cancer. Cancer Res Prev Treat. 2008;35(9). Wu GH, Zhang JY, Lu PX. Association of single nucleotide polymorphism of interferon-ganuna gene+874 site and breast cancer. Cancer Res Prev Treat. 2008;35(9).
25.
go back to reference Skerrett DL, Moore EM, Bernstein DS, Vahdat L. Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest. 2005;23(3):208–14.CrossRefPubMed Skerrett DL, Moore EM, Bernstein DS, Vahdat L. Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest. 2005;23(3):208–14.CrossRefPubMed
26.
go back to reference Wu JM, Bensen-Kennedy D, Miura Y, Thoburn CJ, Armstrong D, Vogelsang GB, et al. The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer. Biol Blood Marrow Transplant. 2005;11(6):455–64.CrossRefPubMed Wu JM, Bensen-Kennedy D, Miura Y, Thoburn CJ, Armstrong D, Vogelsang GB, et al. The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer. Biol Blood Marrow Transplant. 2005;11(6):455–64.CrossRefPubMed
27.
go back to reference Saha A, Dhir A, Ranjan A, Gupta V, Bairwa N, Bamezai R. Functional IFNG polymorphism in intron 1 in association with an increased risk to promote sporadic breast cancer. Immunogenetics. 2005;57(3–4):165–71.CrossRefPubMed Saha A, Dhir A, Ranjan A, Gupta V, Bairwa N, Bamezai R. Functional IFNG polymorphism in intron 1 in association with an increased risk to promote sporadic breast cancer. Immunogenetics. 2005;57(3–4):165–71.CrossRefPubMed
28.
go back to reference Kamali-Sarvestani E, Merat A, Talei AR. Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett. 2005;223(1):113–9.CrossRefPubMed Kamali-Sarvestani E, Merat A, Talei AR. Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett. 2005;223(1):113–9.CrossRefPubMed
29.
go back to reference Zur Hausen H. The search for infectious causes of human cancers: where and why. Virology. 2009;392(1):1–10.CrossRefPubMed Zur Hausen H. The search for infectious causes of human cancers: where and why. Virology. 2009;392(1):1–10.CrossRefPubMed
30.
go back to reference Joshi D, Quadri M, Gangane N, Joshi R. Association of Epstein Barr virus infection (EBV) with breast cancer in rural Indian women. PLoS One. 2009;4(12):e8180.PubMedCentralCrossRefPubMed Joshi D, Quadri M, Gangane N, Joshi R. Association of Epstein Barr virus infection (EBV) with breast cancer in rural Indian women. PLoS One. 2009;4(12):e8180.PubMedCentralCrossRefPubMed
31.
go back to reference Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology. 2009;73(1):32–8.PubMedCentralCrossRefPubMed Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology. 2009;73(1):32–8.PubMedCentralCrossRefPubMed
32.
go back to reference Wingate PJ, McAulay KA, Anthony IC, Crawford DH. Regulatory T cell activity in primary and persistent Epstein-Barr virus infection. J Med Virol. 2009;81(5):870–7.CrossRefPubMed Wingate PJ, McAulay KA, Anthony IC, Crawford DH. Regulatory T cell activity in primary and persistent Epstein-Barr virus infection. J Med Virol. 2009;81(5):870–7.CrossRefPubMed
33.
go back to reference Mi YY, Yu QQ, Xu B, Zhang LF, Min ZC, Hua LX, et al. Interferon gamma +874 T/A polymorphism contributes to cancer susceptibility: a meta-analysis based on 17 case-control studies. Mol Biol Rep. 2011;38(7):4461–7.CrossRefPubMed Mi YY, Yu QQ, Xu B, Zhang LF, Min ZC, Hua LX, et al. Interferon gamma +874 T/A polymorphism contributes to cancer susceptibility: a meta-analysis based on 17 case-control studies. Mol Biol Rep. 2011;38(7):4461–7.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Correlations of IFN-γ genetic polymorphisms with susceptibility to breast cancer: a meta-analysis
Authors
Chun-Jiang Li
Yue Dai
Yan-Jun Fu
Jia-Ming Tian
Jin-Lun Li
Hong-Jun Lu
Feng Duan
Qing-Wang Li
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1856-6

Other articles of this Issue 7/2014

Tumor Biology 7/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine